Nautilus Biotechnology

Nautilus Biotechnology to report Q3 2024 financial results on Oct 29, 2024, with a webcast at 5:30 a.m. PT / 8:30 a.m. ET discussing results and business developments.

Nautilus Biotechnology to report Q3 2024 financial results on Oct 29, 2024, with a webcast at 5:30 a.m. PT / 8:30 a.m. ET. Nautilus aims to democratize proteomics access.

Nautilus Biotechnology's Senior VP of Operations, Mary E. Godwin, sold 47,031 shares for $134,743 and acquired 47,031 shares for $21,634 through stock options. The company reported a Q2 2024 net loss of $18.0 million and anticipates a 2025 commercial launch of its proteomics platform. Nautilus ended Q2 with $233 million in cash and extended its cash runway to H2 2026. Despite a negative P/E ratio, the stock has seen a 25.06% return over the last three months.

Mary E. Godwin, Nautilus Biotechnology's Senior VP of Operations, sold 47,031 shares at $2.865 each on Sept. 23, 2024, totaling $134,743. Post-transaction, she no longer owns any shares.

Nautilus Biotechnology appoints Martin Huber, Ph.D., as VP of Biochemistry and Flow Cell Development, expanding its R&D senior leadership team.

Nautilus Biotechnology's Senior VP of Operations, Mary E. Godwin, sold 35,000 shares at $2.8534 each, divesting her entire stake. Simultaneously, she exercised 35,000 stock options at $0.46 each. The company reported a Q2 2024 net loss of $18.0 million and $20.8 million in operating expenses, yet extended its cash runway to H2 2026. Nautilus plans to commercialize its proteomics platform in 2025, despite funding challenges.